Clinical Trial Update: Tasigna in Glivec-resistant or Intolerant Patients in CML [Phase 4]

View source ↗

Summary

Phase 4 trial results of nilotinib (Tasigna) in chronic myeloid leukemia patients who are resistant or intolerant to imatinib (Glivec). The trial status is comp…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Myeloid Leukemia

Drugs mentioned

• Tasigna (nilotinib)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: CML, Nilotinib | Phase 4 | Status: COMPLETED